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Abstract
High risk Human papillomavirus infections are linked to highly prevalent cancers; a
consequence of aborted viral cycles and deregulation of HPV oncogenes E6 and E7. In
many cases of cancer, meiotic genes can be seen upregulated, activation of meiotic genes in
normal tissue can have detrimental effects due to the unique characteristics of
gametogenesis that if observed in normal cells can be oncogenic. The gene of interest
investigated in this project is SYCP2; it is a meiosis specific gene that is a part of the
synaptonemal complex that links homologous chromosomes and facilitates synapsis.
Recent studies showed it is strongly upregulated in HPV associated cancers when it’s
normal expression should be restricted to testis, it has been linked to what is called Cancer
Testis Antigens (CTA) which are a group of genes that has been associated to tumours of
different histological origins whose normal expression is restricted to testes. This gene is of
interest because CTAs hold unique therapeutic potential as biomarkers or
immunotherapeutics. It has been documented that SYCP2 is upregulated, however, existing
data thus far only shows the mRNA level. In order to explore any therapeutic potential of
this gene its expression profile needs to be investigated, and its possible correlation to viral
infection or oncogenesis. In this project we aim to investigate if the large increase in
SYCP2 transcript levels in HPV16+ cancers is paralleled by a similar increase in SYCP2
protein levels. This study has looked into the protein expression of SYCP2 that if further
investigated, could form a useful model in understanding HPV infection and the possible
role SYCP2 has in aiding oncogenesis.
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1 Introduction
According to the World Health Organization (WHO) 2018 registered 570 000 new cervical
cancer cases in the world, which accounts for 7.5% of female cancer mortality. Human
Papillomavirus (HPV) is a DNA virus of the reproductive tract, HPV infection is attributed
to sexual activity and found highest in females aged 30 to 34. There are over 100 strains of
HPV with characteristic tropism, And around 12 types of HPV strains are considered high
risk that lead to cancer. The HPV infection can be asymptomatic or can present as warts
that are either Cutaneotropic in which they present as benign or malignant cutaneous and
plantar warts, or Mucosotropic which present as benign or malignant genital warts.
(Castellsagué, 2008). The viral infection can take up to 15 years to develop to precancerous
lesions, preventative measures are advised; primary prevention by vaccination which is the
best preventative approach to reduce global cervical cancer burden, and secondary
prevention by screening using molecular biology techniques to detect the presence of the
virus, the persistence and viral load per unit as well, as the type of HPV plays a role in the
risk of oncogenesis. (Human papillomavirus (HPV) and cervical cancer, no date)
Scientific research over the last decades has demonstrated the causal effect of persistent
HPV infection and cervical cancer, and has been claimed to be the first necessary cause of a
human cancer ever identified. (Bosch et al., 2002) (Castellsagué, 2008) HPV+ cancers
present a unique molecular profile in regards to mutation burden, intratumoral
heterogeneity as well as epidemiological profile. (Lechner and Fenton, 2016) Due to the
11
Aroub Yousef I Almubarak
unique mutational signature of HPV+, in which the HPV oncoproteins introduce uniform
mutations to host genes in the DNA repair machinery, this provides more targeted
biomarkers and treatments which in turn provides more radiosensitivity. HPV+ cancers
proved to have better clinical prognosis and better disease-free survival. Thus a patient’s
HPV status presents an advantage to the patient’s response to treatment and survival. (Faraji
et al., no date) (Gillison et al., 2019)
HPV presents a good model for studying alterations that lead to oncogenesis for the
uniform and systemic mutations it introduces to host cells. This project focuses on a
meiosis specific gene that has been documented to be upregulated in HPV+ cancers. We
aim to investigate its possible role in HPV infection and/or tumour progression.
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Literature Review
1.1 Cancer Biology
Cancer is a collection of diseases that can affect any organ or type of cell. It is more a
pattern in which cells deviate from the complex highly intricate structure of cellular
maintenance. Essential Cell Biology Alberts B Hopkin K Johnson A et al. identifies cancer
with two characteristics: (1) Proliferation in defiance of normal cellular constraints and (2)
invading and colonising other cells’ territories. (Alberts et al., 2019)
Epidemiological studies have shown that environment and life style is an important role in
the causation and progression of human cancers. And that shows in how different cancer
types are more prevalent in different countries. For example, cervical cancer is more
common in sexually active women and almost 99% of cervical cancers are caused by
sexually transmitted virus HPV. (Moody and Laimins, 2010) However, even with the strong
correlation of life style and environment, there is still much not known of the specific
factors that drives oncogenesis, that could be due to the fact that studying cancer cells in
vitro is not a true representation of the in vivo model. Especially the interactions and
scaffolding of the extracellular matrix (ECM), that and the biochemical nature of the
tumour microenvironment (TME) in different organs, such as pH, oxygen, nutrient and
waste diffusion. The varied nature of TME and metabolic differences in each location or
tissue adds the complexity of the physiology and subsequent severity of the cancer in a
specific location, phenotype advancement and surrounding tumour stroma transformation
13
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(Alberts et al., 2019) (Burgos-Panadero et al., 2019). For a cell to become cancerous it
accumulates mutations; which are changes in the DNA sequence. This can happen through
external stressors such as smoking, UV rays, radioactivity, and chemical carcinogens.
However, even in an environment without these mutagens, mutations can still arise
spontaneously through mistakes during the DNA replication process in cell division.
Although DNA repair is a highly accurate and precise mechanisms mistakes may happen in
which they introduce a mutation and this mutation would be carried out through this cells
progeny (Alberts et al., 2019).
1.1.1 Cancer and Epigenetics
The regulations and patterns of gene expression that do not entail any change in the DNA
sequence and can be passed along to a cell’s progeny is called epigenetic inheritance. A
mechanism in which DNA expression is altered but without the change of the sequence is
DNA Methylation in which a methyl group is added to the fifth carbon of cytosine residue
to form 5-methylcytosine. This process is carried out by a family of DNA methyltransferase
(DNMT), in addition to carrying out the formation of 5-methylcytosine they also during
DNA replication carry out the DNA methylation pattern from parental DNA to daughter
DNA. The specific process in which the DNMTs target these sites are unclear but there is a
proposed mechanism in which RNA interference (RNAi) targets DNA sequences and
silences them.
14
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(Reece et al., no date) This conserved process is what allows the variety of different gene
expression in different cell types given the fact that essentially all cells share the same
genome. When epigenetically silenced genes are activated there can be detrimental effects
that lead to cancer.  (Moore, Le and Fan, 2013)
Not all mutations cause cancer, there needs to be a very specific favourable environment for
cancer cells to replicate as they do, such as the disruption of tumour suppressor genes, cell
cycle regulating genes and promoting genetic instability. And it is with these
characteristics, these cells would proliferate when they should not, and not follow the
specific cellular instructions. It is not only one single mutation that would lead to tumour
development it can take up to ten mutations. It is of importance to study the molecular
environment in which these cellular violations happen to offer better more effective
therapeutic options (Alberts et al., 2019).
With the advancement of sequencing we have come to know the different mutational
signatures of different tumours. Because cancer is not only one disease, analysing
mutational profiles helps identifying driver mutations, and characterising the biology that
creates the advantageous processes that ultimately promote tumorigenesis and help the
discovery of biomarkers and personalised treatments.
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1.2 Cancer Testis Antigens
Cancer Testis Antigens (CTA) are tumour associated antigens which are expressed in
tumours of various histological origins. In normal tissue, CTA are almost exclusively
expressed in the seminiferous tubules of the testes during spermatogenesis modulating
meiosis. Epigenetic regulation might be the mechanism in which CTA expression is
regulated, DNA methylation in particular. Epigenetic regulation protects cells from entering
what is called ‘soma-to-germline transition’ which is when somatic cells gain cellular
functions that are specific to germ line cells. When somatic cells gain meiosis specific
functions, such as using interhomolog recombination, this gives rise to aberrant
proliferation which in turn could lead to loss of tumour suppressor genes and genomic
instability, which as previously described are hallmarks of cancer. CTAs have become a
pharmacological target because of the nature of their tumour restricted pattern of expression
that can allow for tumour directed immunotherapeutics. (Fratta et al., 2011), (McFarlane
and Wakeman, 2017)
1.2.1  Expression pattern and therapeutic potential of cancer testis antigens
In the early 1960s, the use of serological analysis and experimentations on mice showed
that transplanting mice with certain tumours triggers an antigenic immune response. This
finding cultivated an interest in the field because it showed the potential of employing the
immune system’s cytolytic activity to treat cancer (Whitehurst, 2014).
16
Aroub Yousef I Almubarak
One of the first identified CTA family of antigens was by Van Der Bruggen and colleagues
in 1991 termed MAGE-1. They are expressed in melanoma cancer cells, and further studies
into this family of antigens showed the normal expression of this family of genes MAGE-1
is restricted to testis. (Van Der Bruggen et al., 1991) These antigens are characterised by
their mRNA expression being specific to germ cells, and their abnormal gene activation in
non-germ cells is often linked with tumorigenesis. (Gibbs and Whitehurst, 2018) However,
some have reported low expression in somatic tissue (<1% of their mRNA expression in
testis) (Fratta et al., 2011) There is reported low expression in the brain and reported
presence in placenta and ovary and earlier stages of embryogenesis. (Whitehurst, 2014)
(Costa, Le Blanc and Brodin, 2007)
Following the discovery of the first family of Cancer Testis Antigens MAGE-1 and their
potential in immunotherapy, many other CTA family of antigens were discovered. The
availability of cloning methods and use of cDNA libraries led to the identification of over
225 genes such as: GAGE-1 (Van den Eynde et al., 1995), BAGE (Boël et al., 1995)
HOM-MEL-40 (Sahin et al., 1995) SSX2 (Kawai et al., 1998) and NY-ESO-1 (Chen et al.,
1997). The data showed that CTAs are more likely to be activated in lung, ovarian, bladder,
melanoma and breast tumours, and less likely to be activated in leukaemia, lymphoma,
renal, colon, and pancreatic tumours (Whitehurst, 2014).
In somatic tissue CTA are usually methylated, As mentioned previously; methylation is a
molecular phenomenon where genes are silenced by the addition of methyl groups to the 5’
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of cytosine in the cytosine-guanine dinucleotides in gene promoters. Catalysed by DNA
methyltransferases (DNMTs), this process represses the expression of genes, with the help
of chromatin remodelling co-repressor complex, binding methyl-CpG-binding protein
(MBDs) (Figure 1). And in spermatogenesis CTAs are activated by demethylation. De novo
expression of MAGE-A1 one of the first CTAs to be investigated correlated this pattern of
expression in melanoma cell lines. The hypomethylation pattern of expression is also
observed in different MAGE-A and NY-ESO when investigated in cell lines. This proposes
an epigenetic alteration module of expression for CTA (Fratta et al., 2011).
Figure 1 Epigenetic regulation of CTA expression.
(A) CTAs are silenced in normal tissue, the chromatins are methylated and that is facilitated by DNA
methyltransferase DNMT, binding of transcription factors is inhibited as there is no access to the promoter
region. (B) In the absence of DNMTs transcription factors have access to promoter regions and result in
transcriptionally active CTA genes. Figure adapted from: (Fratta et al., 2011)
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CTAs are potentially a good target for immunotherapy as they showed an immunogenic
response in recruiting the Cytotoxic T Lymphocytes (CTLs) in experimental models.
Considering the low immunogenicity and immunosuppressive microenvironment of
tumours makes for a good target for cancer vaccine. A study conducted in 2005 showed
that infecting melanoma cells with ALVAC, a virus encoding MAGE antigens recognized
by T-cells has showed that with repeated vaccination tumour regression and a CTL
response is observed in a minority of melanoma patients (Van Baren et al., 2005) (von
Witzleben et al., 2020).
Any gene whose expression is restricted to testis + neoplastic cells can be classified CTA.
However, classification by expression data alone may not translate to the antigen’s
immunogenic status and its ability to elicit humoral and cellular immune responses and
need to be further investigated. Expression patterns of testis-tumour genes and their
possible therapeutic potential warrant further investigation, and in this project one specific
testis gene will be investigated, SYCP2.
19
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1.3 Human Papillomavirus
1.3.1  HPV structure and genome organisation
HPV is a circular double stranded non enveloped virus that is around 8000 bp, 50–60 nm in
diameter and belongs to the Papillomaviridae family and weighs at 5x106 Dalton, it is
evolutionary conserved with a divergence rate of 1% per 40,000-80,000 years. There are
more than 240 types of HPV, and can be classified into low risk and high risk. 12 types are
known to be associated with malignant lesions and drivers of oncogenesis. Of those types
HPV-16, HPV-18, HPV-31 and HPV-33 are the most high risk types, making up 75% of all
HPV associated squamous cell carcinoma and 94% of adenocarcinomas. 30% of females
exposed to oncogenic HPVs are infected within 24 months post sexual exposure, 90% clear
within 2 years but persistent prolonged infection may lead to cervical intraepithelial
neoplasia (CIN) (Araldi et al., 2018a) (Serrano et al., 2015) (McBride, 2017c)
The virus has 8 Open Reading Frames (ORF) which through the method of alternative
splicing encode the following genes; E1, E2, E5, E6, E7 and capsid proteins L1 and L2.
These proteins help make an environment where a productive viral life cycle can be
achieved. (Van Doorslaer, 2013) (Araldi et al., 2018a) The genome as shown in (Figure 2)
contains three regions; Upstream Regulatory Region (URR) that controls transcription and
early region encoding the early proteins and lastly the late region encoding the late
proteins.(McBride, 2017c)
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Figure 2 Figure shown is the genome of circular double stranded DNA of Human Papillomavirus. Photo Credit:
McBride, Alison A. “Mechanisms and strategies of papillomavirus replication.” Biological chemistry vol. 398,8
(2017): 919-927. doi:10.1515/hsz-2017-0113 (McBride, 2017a)
1.3.2   The HPV life cycle
i. Viral Entry
The method of infection of HPV is through the epithelia, skin cells, oral and genital
mucosa. Sexual contact is its known method of infection and so an individual’s sexual
behaviour and possible multiple sexual partners can be attributed to be the risk factor.
However in the case of HPV-42 and HPV-16 there has been reported vertical mode of
transmission; from mother to new-born. The virus gains entry through micro abrasions and
infects the basal cells, taking advantage of the wound healing process which is an
environment of high proliferation and self-renewing cells. The capsid protein of the virus
21
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L1 binds to heparin sulphate proteoglycans on the basement membrane inducing a
conformational change allowing the virus to bind to the surface of the basal cells. (Day and
Schelhaas, 2014)
Through the process of endocytosis the virus is engulfed, where the capsid protein L1 is
removed and only the HPV mini chromosome L2 complex remains. And through
endosomal trafficking the HPV genome-L2 complex finds its way to the trans-Golgi
network. When the cell undergoes mitosis and the nuclear envelope breaks down the
L2-HPV genome complex gains access to the nucleus.
ii. Viral genome replication in the basal layer
HPV generates most of its progeny virions in stratified epithelia, however, it starts its virus
life cycle in the basal cells generating in low copy numbers and as the cell differentiates
and moves up the epithelium otherwise known as differentiation dependent life cycle, it
takes advantage of that process and proliferates more copies of the virus and packages
them, and when the cells are shed as a part of the natural tissue renewal process the newly
packaged virions are released and find a new host. (Figure 3) (Stanley, 2012) (Chow,
Broker and Steinberg, 2010)
As mentioned previously the HPV genome-L2 complex gains access to the nucleus after
mitosis and nuclear envelope breakdown, during that process the HPV genome-L2 complex
is observed localising alongside Nuclear Domain 10 (ND10) nuclear bodies and to create a
22
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microenvironment favourable for viral transcription and replication, L2 changes Daxx and
sp100 localisation in ND10 body to allow for transcription and replication of HPV DNA.
(McBride, 2017b) In this first stage viral infection ‘establishment’ in the basal layer the
virus and specifically viral genes E1 and E2 mediates constant low level of transcription
and DNA replication as an extrachromosomal circular genome and it is passed down to
daughter cells with every cell division. This conserved process along with the tethering of
the HPV genome-L2 complex to immune hotspots such as the ND10 nuclear body is
thought to be why HPV can escape immune recognition. (McBride, 2017c)
Early region genes encode the early proteins. E1, E2, and E4 HPV proteins, which as
mentioned previously are essential to initiate virus replication. With E1 being the most
conserved sequence in the whole of the papillomaviruses, E1 interacts with E2 to form a
complex called the E1-E2 complex and initiates ori dependent replication. E1 also acts as a
helicase binds and unwinds DNA allowing for access to the replication process. E1 initiates
viral replication when its N-terminal domain binds to the motif region of Cdk2(Ma et al.,
1999). The complex initiated by E1-E2 attracts topoisomerase 1, and DNA polymerase α
and replication protein A (RPA) (Araldi et al., 2018a). An important role for E2 is that it
acts as a transcriptional regulator for HPV oncoproteins E6 and E7 and regulates the
amount of virions produced in a cell as it is responsible for the recruitment of the
transcription factors required to initiate replication ensuring that only limited number of
viral copies are being amplified during the early stages (Cai et al., 2013).
23
Aroub Yousef I Almubarak
iii. Viral genome maintenance
The viral life cycle of HPV goes through initial amplification to establish the steady low
copy replication maintained in the second stage; maintenance. Which is carried out in
constant low copy numbers as an extrachromosomal episome providing indefinitely a pool
of viral infected cells to ensure persistence infection. They are estimated to be around 20
viral copies per cell.(McBride, 2008)
Furthermore, HPV protein E2 plays a role in the passing down of viral DNA to daughter
cells by forming a complex with the protein Brd4. E2 forms the complex by binding the
Brd4 protein to its C-terminal domain forming a complex that tethers the viral genome to
the host chromatin, this process is what allows persistent infection by making sure of
successful partitioning of DNA through the stable association with host chromatin in which
they would remain in the nucleus membrane after cell division and pass down the HPV
genome to daughter cells. (Helfer, Yan and You, 2014)
An important result of the interaction of Brd4 and E2 is binding to common fragile sites
and because of the unique property of these sites E2 is able to induce, hijack and facilitate
the DNA damage response (DDR) to produce the viral progeny (Jang, Shen and McBride,
2014)
24
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iv. Viral Amplification and Packaging
As the cell starts to differentiate and move up the epithelium, the virus takes advantage of
the differentiation process and employs the host cell machinery to produce its viral progeny.
Helping this process is spliced mRNA product viral protein E4, E1^E4 it interferes with the
cell cycle to achieve the S phase like state to allow for viral DNA amplification (McBride,
2008). HPV oncoprotein E7 drives the host cell into S phase and E1^E4 arrests the cells in
G2 phase as it is where the virus can achieve higher viral DNA amplification. In this stage
the DDR pathway is activated by an E7 induced interaction with ATM, and the DNA repair
machinery in the DDR pathway is hijacked and used to amplify viral DNA in a favourable
site via the interaction of E2-Brd4 mentioned previously (Moody and Laimins, 2009).
Figure 3 The different stages of the papillomavirus life cycle.
The figure shows cells of differentiated stratified epithelium, the arrow pointing downwards shows how HPV
gains access to the cells of the basal layers through micro abrasions. Which is where HPV begins initial DNA
amplification and establishes maintained viral genome replication in sync with host genome replication. The
arrow pointing upwards shows as the infected cells begin to differentiate, they begin amplifying viral DNA at a
higher number and  begin viral DNA packaging and the assembly of the virion capsid, and thereafter viral laden
cells are sloughed off ready for a new host. Photo Credit: McBride, Alison A. “Mechanisms and strategies of
papillomavirus replication.” Biological chemistry vol. 398,8 (2017): 919-927. doi:10.1515/hsz-2017-0113
(McBride, 2017a)
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As mentioned, Viral DNA amplification happens in G2 arrested cells, and not in S phase
where the host DNA is amplified. The reasons behind the viral DNA amplification
happening after host DNA amplification are not widely understood, but it has been
suggested that the host cell replication machinery is easier to hijack and can amplify DNA
efficiently and more rapidly when it is not engaged with the replication of the host DNA
(Wang et al., 2009). Highest viral amplification occurs in terminally differentiated cells, the
reason behind that could be that differentiated cells have less immune surveillance
(McBride, 2017a). And subsequent to that the morphogenesis of progeny virions is
observed.
The viral capsid packaging is facilitated by the late region genes, which encode L1,L2 the
major capsid proteins. L1 protein mediates the binding of the virion to heparin sulphate
receptors that are on the surface of the basal membrane giving the structural characteristics
that allows it to invade cells. L2 is important in the first stages of the viral cycle as well as
the last, as it mediates the DNA packaging and the assembly of the virion capsid. (Buck,
Day and Trus, 2013) (McBride, 2017a) In the final stages in terminally differentiated cells,
the packaged virion progeny is found throughout the nuclei, the viral genome is condensed
into chromatins with host histones inside the viral capsid. And with the tissue renewal
process these viral laden cells are sloughed off ready to infect a new host.
26
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1.3.3 HPV induced Oncogenesis
Most HPV present as benign lesions or (papilloma), but some high risk HPVs have evolved
through persistent infection and interfering with cellular pathways leading to onset of
oncogenesis. Which include but not limited to cervical cancer, head and neck cancer and
oropharyngeal squamous cell carcinoma (OPSCC). As previously discussed HPV genetic
amplification happens with alteration in the cell cycle of through recruited DDR, in that
when the differentiated cell should have already exited the cell cycle, for that proliferative
state to be maintained E7 disrupt many important cell cycle regulators disrupting pathways
such as pRb, p107, p130. And a consequence of HPV oncoprotein E7 through these
molecular events leads to the activation of p53 tumour suppressor pathway.
E6 HPV oncoprotein plays a role in cell immortalization, by causing an upregulation in the
expression of the human telomerase reverse transcriptase (hTERT) gene. And it also
upregulates the expression of the NKX2-1 which in turn upregulates FOXM1 in HPV
associated head and neck carcinoma that induces B-catenin nuclear translocation, these
series of events often lead to the proliferation of keratinocytes and subsequent
tumorigenesis (Araldi et al., 2018b). Furthermore, E6 similar to E7, would too alter the
effects of the tumour suppressor protein p53. This happens through E6 forming a ternary
complex with E6AP ubiquitin ligase and p53 leading to the degradation of p53.
Mutations in p53 are linked to uncontrolled proliferation, and developmental defects. This
phenomenon is linked to tumour progression because of the fundamental role p53 plays in
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regulating gene expression, p53 responds to acute stress cell signals which are often a sign
of oncogenic progression by driving the cell into programmed cell death. (KH and DP,
2007),(Rivlin et al., 2011).
In addition, E6 can play a role in the genetic instability of the host genome by interacting
with proteins responsible for single strand DNA break repair, and by that introducing
mutations leading to cancer initiation. E6 can work with E7 to induce mutations and genetic
instability as their co-expression has been shown to induce extracellular matrix
remodelling, they also work to evade the immune system by downregulating Toll Like
Receptors (TLR), and thus escape virus recognition and the activation of phagocytes
(Araldi et al., 2017) (Cai et al., 2013).
The E5 gene encoding E5 HPV oncoprotein is a hydrophobic transmembrane protein; this
protein is associated with cancer progression because of its mitogenic activity. The
oncoprotein E5 can trigger cellular proliferation by changing the endosomal ph from 5.9 to
6.9 which inhibits the degradation of the Epidermal Growth Factor (EGF) and it can work
together with EGF to recycle back the receptors from endocytosis to the cell membrane. E5
loses its Open Reading Frame (ORF) after genome integration which further suggests that it
is involved in the early processes of cancer progression.(Gutierrez-Xicotencatl et al., 2020)
E5 can also be found on the golgi apparatus (GA) and Endoplasmic Reticulum (ER). E5’s
interaction with GA interrupts the major histocompatibility class I encoded protein human
leukocyte antigen (HLA) which are important for immune regulation, interrupts its
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expression on cell surface, this allows the virus to evade immune recognition and thus
allow for viral-infection persistence. In addition, E5 uses Bax ubiquitination to inhibit
apoptosis in cervical cancer; this leads to oncogenesis (Araldi et al., 2018b).
This continued viral persistence and maintenance of the transformed state of the host cell
when it should have exited the cell cycle, with the aforementioned characteristics of genetic
instability could lead to genomic integration. E1 also aids with HPV viral integration by
eliciting DNA breaks in the host genome. And this result is not necessarily a part of the
virus life cycle because viral genomic integration might actually be considered the
dead-end of a productive viral infection as no progeny virions can be produced going
forward.
As mentioned previously E2 acts as a transcriptional regulator for E6 and E7, facilitating
cell immortalisation and evading immune recognition. When the HPV genome is integrated
onto the host genome E2 regulation is disrupted and a dysregulation in the expression of E6
and E7 HPV oncogenes is observed, and what it creates of an environment of uncontrolled
proliferation, and genetic instability and these are often the hallmarks of cancer progression
(Jang, Shen and McBride, 2014) (McBride and Warburton, 2017).
HPV disrupts a number of host genes, investigating these alterations opens a myriad of
possibilities such as vaccines, biomarkers for early detection, and personalised treatments
through neoantigens; where cancer treatment allows for the eradication of cancer cells with
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less harm to healthy cells. In this project we investigate a meiosis specific gene upregulated
by HPV, SYCP2.
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1.4 Synaptonemal Complex
Meiosis is the molecular process observed in sexually productive organisms resulting in
spermatozoa and oocytes in the case of mammals. What distinguishes this process from
mitosis is that instead of the production of genetically identical diploid daughter cells,
meiosis results in haploid gametes, with one copy of either paternal or maternal
chromosomes. The unique and defining event in meiosis is the highly conserved and
controlled molecular process called crossing over, where maternal and paternal
chromosomes are tethered by a protein complex called the Synaptonemal Complex pair in
an X shaped structure called the chiasma facilitating meiotic recombination where
programmed DSB are initiated and repaired. This genetic exchange observed in meiosis is
allowed to happen because of the favoring of inter-homologous DNA repair as opposed to
inter-sister DNA repair observed in mitosis.
1.4.1  The Synaptonemal Complex role in DNA replication
During the cell cycle, the cell undergoes double strand breaks (DSB) from different
stressors; ionizing radiation, reactive oxygen species, Ultraviolet light, DNA replication
errors, as well as regulated DSB to facilitate recombination in meiosis induced by SPO11,
in which DNA DSB repair pathways are recruited. DNA repair pathways include; Non
homologous End-Joining (NHEJ) which is predominantly used during cell cycle, it does not
need a homologous template and is facilitated by directly re-ligating the broken ends
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together. If NHEJ fails and there is damage from the broken ends, Microhomology
Mediated End Joining (MMEJ) is recruited which includes resection of the broken ends to
mediate homology. This pathway is associated with deletions and chromosomal
abnormalities. (Pardo, Gómez-González and Aguilera, 2009) Homologous Recombination
(HR) DNA repair pathway, which includes inter-sister and inter-homologue recombination,
relies on the access of a homologous template. In mitosis we witness a favouring of
inter-sister HR, it is present in the G2 phase of the cell cycle because that is when the
chromosomes are duplicated. In meiosis I, we witness inter-homolog HR bias, this occurs
in the pachytene stage of prophase 1, inter-homolog recombination is important in meiosis
because it creates genetic variety to the offspring. The Recombinase proteins facilitate
recombination (Rad51-Rad54 in eukaryotes) by searching for homology and then,
promoted by HORMAD-1 (meiotic HORMAD proteins regulate DSB and crossover
formation) ‘presynaptic alignment’ is then formed and the synaptonemal complex (SC)
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Figure 4 Model of the elements of the synaptonemal complex. Photo Credit: Molecular Biology of the Cell by
Alberts, Bruce; Johnson, Alexander; Lewis, Julian; Raff, Martin; Roberts, Keith; Walter, Peter New York and
London: Garland Science; c2002
1.4.2  The importance of the Synaptonemal Complex for chromosome alignment during
meiosis
The Synaptonemal Complex comprises of; axial elements (AE) precursors of lateral
elements (LE) in synapsis, and transverse filaments (TF) to make up the mature SC.
Synapsis occurs by: AE forming between sister chromatids, the AEs of two homologous
chromosomes are connected by the TFs and when SC disassembles, homologous
chromosomes are separated except at crossover regions which are called chiasmata. (Del
Val et al., 2019) (nd Kelsey C. MartinMhatre V. Ho, Ji-Ann Lee, 2012) (West et al., 2019)
Components of this proteinaceous structure are: SYCP1; SYCP2 and SYCP3. Together
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they form a heterotetrameric coiled-coil complex that self-assembles into extended
filaments. Cohesin complexes interact with HORMAD proteins and SYCP2/SYCP3 and
make up the mammalian meiotic chromosome axis. This process is conserved across fungi,
mammals, and plants.
Mutations in SC are linked to male infertility, the AEs fail to form and no synapsis is
witnessed and that leads to improper segregation of chromosomes at meiotic metaphase I,
creating genomic instability and leads to aneuploid gametes.(Yang et al., 2006) (Geisinger
and Benavente, 2017)
SYCP3 is required for the recruitment of SYCP2 but not SYCP1, they are structural
components of AE/LE. The synaptonemal complex facilitates synapsis because it is a part
of the chromosome axis core proteins, and seen during the pachytene stage of meiosis I
because it links homologous chromosomes together and aids crossover.
1.4.3  The Synaptonemal Complex’s role in suppressing inter-sister recombination during
meiosis
In addition, a study published in 2011(Li, Bolcun-Filas and Schimenti, 2011) explored that
SCs role in meiosis is not only a structural role and mediating proper chromosome
segregation, but that the SC also plays a role in recombination partner choice by creating
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inter-homolog bias in the repair of programmed meiotic DSB (West et al., 2019) (Yang et
al., 2006) (Li, Bolcun-Filas and Schimenti, 2011) .
The study started with the observation that a proportion of oocytes in SYCP3-deficient
female mice nevertheless survive despite the fact that the SC is unable to assemble. This is
counterintuitive, since in the absence of the SC normal meiotic recombination cannot occur.
Thus, oocytes from SYCP3-deficient females would be expected to show persistent
unrepaired DNA damage, triggering apoptosis.
Their first hypothesis was that the SC plays a role in the DNA damage checkpoint. In this
case, this check point would be lost in SYCP3-null oocytes, allowing them to survive
despite persistent DNA damage. To test that theory they created a SYCP3 mutant, a Rec8
mutant and a SYCP3, Rec8 double mutant. A Rec8 mutant inhibits the sister chromatids
from binding and subsequently prevents synapsis between homologs which in turn prevents
all recombination inter-sister or inter-homologous and subsequent repairs to DNA damage,
therefore spermatocytes and oocytes would be eliminated by the DNA damage checkpoint.
If the SC plays a role in the DNA damage checkpoint then SYCP3 deficiency should be
able to rescue the effects of Rec8 mutation, allowing oocytes to survive in the double
mutant females. However, the double mutant showed no viable oocytes indicating that
these have a functional DNA damage checkpoint despite lacking SYCP3.
35
Aroub Yousef I Almubarak
This led to an alternate hypothesis: that when SYCP3 is knocked out DSB are repaired by
NHEJ instead of by HR. To test this second hypothesis, they used the severe combined
immunodeficiency (scid) model which lacks the PRKDC gene required for the
non-homologous end joining (NHEJ) pathway of DNA repair. If DSBs in SYCP3-deficient
oocytes are repaired by NHEJ, then the SYCP3, scid double mutant should be unable to
repair meiotic DSBs and this double mutation should prevent oocytes survival. However
the SYCP3, scid double mutant showed viable oocytes and that eliminated the theory that
NHEJ repairs DSB introduced by SPO11 in meiosis.
Figure 5 Model for role of axial element in promoting interhomolog recombination bias proposed by Li, Xin
Chenglin et al. “Genetic evidence that synaptonemal complex axial elements govern recombination pathway
choice in mice.” (2011) (Li, Bolcun-Filas and Schimenti, 2011)
This led to their third and final hypothesis that SYCP3 affects the choice of template used
for DNA repair by HR. To test the third hypothesis they used Rad54 and Dmc1 mutant and
double mutant females in combination with SYCP3 mutations. RAD54 is essential for
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inter-sister recombination, while Dmc1 is essential for inter-homolog recombination.
Dmc1 mutant females lack oocytes, showing that the normal pathway for DNA repair in
oocytes strictly requires inter-homolog HR. The DMC1/SYCP3 double mutant is viable,
but with a lower oocyte count. This shows that SYCP3 must facilitate the repair of meiotic
DSBs by some pathway other than inter-homolog HR. The DMC1/RAD54/SYCP3 triple
mutant lacks oocytes, showing that the rescue of oocyte loss in the DMC1/SYCP3 double
mutant must require a functional pathway for inter-sister HR (Figure 5).
The conclusion is that one function of the synaptonemal complex during meiosis is to
suppress inter-sister HR, and that loss of the synaptonemal complex permits the repair of
meiotic DSBs by inter-sister HR. Although focused on Sycp3, this study did also
investigate a double mutation of Sycp2 and Trip13, and concluded that loss of either Sycp2
or Sycp3 can relieve the block to inter-sister HR.
1.4.4 The Synaptonemal Complex gene SYCP2 expression in cancer
The gene investigated in this project SYCP2, is of interest because of its upregulation in
HPV associated cancers. Published data analysing RNA expression by conducting wide
RNA sequencing for transcripts with possible statistical significance found that SYCP2
showed the most significant upregulation from baseline to premalignant tissue; higher than
CDKN2A, which is used as a clinical biomarker for HPV in OPSCC (Slebos et al., 2006)
(Masterson et al., 2015).
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Furthermore, our research group previously demonstrated that SYCP2 is part of a set of
genes that are consistently upregulated in HPV+ cancers, irrespective of the anatomical
location at which they arise (Chakravarthy et al., 2016)
Figure 6 Expression of SYCP2 and HPV oncoprotein E6 of RNA samples from both HPV+ and HPV- cancer
cell lines. Data is obtained from previous Dr. Tim Fenton, Dr. Peter Ellis collaboration student Cindy Dong.
Data from genomic analysis of cervical cancers caused by different HPV types by the
Fenton lab (Chakravarthy et al., 2020) suggests SYCP2 upregulation is specifically seen in
cervical cancers caused by HPV types in the alpha-9 clade which include HPV16, but not in
the alpha-7 clade, of which HPV18 is a member. Moreover, previous MSc-R student
(Cindy Dong) confirmed using qRT-PCR, the upregulated expression of SYCP2 in HPV
associated cancer cell lines (Figure 6). As can be seen in the figure there is significant
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upregulation in HPV 16 cancer cell lines. However, existing data only shows expression on
the mRNA level,
There is no existing data assessing the protein expression of SYCP2, confirming that
mRNA expression is followed by protein expression would be a stepping stone into
exploring the possible role this gene may have in viral infection or cancer progression or
both. Which is why it is one of the aims of this project. Exploring the expression pattern of
the gene interest can open the possibility of finding a non-invasive screening tool for HPV
specific cancers. Moreover, existing literature does not provide sequenced analysis of final
protein structure of the wrongfully expressed form of SYCP2, it could be that the protein
product being expressed in HPV+ cancer is an alternatively spliced form of SYCP2, as
opposed to the much larger full length expressed in testes. (Shakib et al., 2005) (Guo et al.,
2020)
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2 Aims
As presented through the literature review; our gene of interest has been linked to HPV+
cancers. The mRNA data available showing the significant upregulation from baseline to
premalignant tissue warrants further investigation, considering the potential it has in
creating a non-invasive screening tool. In view of this, we present the following
hypotheses:
Hypothesis 1: Overexpression of SYCP2 on the mRNA level is linked to overexpression of
SYCP2 on the protein level.
Hypothesis 2: Noncanonical expression of SYCP2 is linked to oncogenic progression.
We aim to test the presented hypotheses by exploring the available genomics data using
bioinformatic tools. By conducting a bioinformatic review of SYCP2 expression across
different tissues, illustrating the differential expression in normal and cancer tissue.
Furthermore, Using a wet lab approach investigate the protein expression pattern of SYCP2
in HPV associated cancer cell lines, and on that explore if the noncanonical upregulation of
SYCP2 mRNA in HPV+ cancer cell lines is linked to upregulation in SYCP2 protein. And
lastly, to investigate the role of SYCP2 in sustaining HPV infection, by the use of SYCP2
knockout cells.
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3 Methodology
2.1 Bioinformatics:
Online bioinformatics tools were accessed to explore the expression profile of the gene
investigated in this project including: GTEx Portal(GTEx Portal, no date) which is a
database encompassing different expression profiles of genes in normal tissue. And
CBioPortal for cancer genomics (CBioPortal, 2013)
2.2 Tissue Culture:
2.2.1 Cell lines
The cancer cell lines in this study (see Table 1) were cultured with Dulbecco’s Modified
Eagle Medium (DMEM) supplied with 5% foetal bovine serum (FBS) and 1%
penicillin/streptomycin. And incubated in 37℃ and 5% CO2. Media was changed
according to the state of the cells 48-72 hours. And when the appropriate confluency of
cells has been reached it is then passaged; washed with 1x Phosphate Buffered Saline
(PBS) followed by 0.05% Trypsin-EDTA and when the cells have detached, diluted with
DMEM and spun down 300 G for 6 minutes and resuspended in fresh DMEM and plated
onto fresh T75 culture flasks.
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Table 1 Mammalian Cell-lines
2.3 Protein Analysis:
2.3.1 Protein Extraction
Cells were grown in 6-well plates 500,000 cells per well to be treated with MG132 which is
a proteosome inhibitor to stabilise the protein and avoid degradation. The cells were treated
in 6 different time intervals; 25uM of MG132 4 hours, 3 hours, 2 hours, 1 hour, 30 minute,
and a control; 25uM DMSO. To extract the protein; first the cells were washed with cold 1x
PBS on ice to ensure low protease activity and then the cells were lysed using Lysis buffer (
960uL MPER + 40 uL Protease inhibitor + 0.4 uL Benzonase) 50 uL for each well, using a
cell scraper the cellular contents collected in 1.5 mL Eppendorf tubes lysed on ice for 15
minutes. Following that, the samples were spun down in a 4℃ centrifuge for 20 minutes at
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10,000 rpm. The supernatant collected and put in final 1.5 mL Eppendorf tubes ready for
Protein Analysis. And pellets saved for later experiments.
2.3.2 Protein Quantification
Obtained protein samples were quantified for subsequent experiments, for this the
ThermoFisher Pierce™ BCA Protein Assay Kit was used. This Assay helps measure
protein concentrations in whole cell lysates to allow for calculation of final ug/uL
concentrations.
2.3.3 Samples prep
Quantified samples were prepared for western blotting by mixing with 4x Laemmli buffer:
[final conc. 277.8 mM Tris-HCL PH6.8 , 4.4% SDS , 44.4% glycerol , 0.02% Bromophenol
blue] + 1M Dithiothreitol (DTT) samples mixed and placed in heat block for 10 minutes in
95℃.
2.3.4 SDS PAGE
The samples were loaded with 5 uL of (Thermo Scientific PageRuler™ Plus Prestained
Protein Ladder) run in a 8% hand-cast gel of which final concentration is [40% Acrylamide
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, 1.5M Tris-HCL PH 8.8 , 10% SDS , 3.75 uL TEMED , 10% APS] And run in Running
buffer (Invitrogen NuPAGE™ MOPS SDS Running Buffer) at 150v for 1 hour.
2.3.5 Western Blotting
Multiple approaches were attempted to optimise transfer.
a. Semi-dry transfer
The samples were transferred on a PVDF membrane using the BioRad Trans-Blot Turbo
System for 20 minutes following manufacturer protocol.
b. Wet transfer
The samples were transferred to PVDF membrane via a wet tank transfer using Towbin
Transfer Buffer (Towbin et al. (1979) PNAS USA 76:4350-4) (Towbin, Staehelin and
Gordon, 1979) is the buffer of choice for tank blotting; 25 mM Tris, 192 mM glycine,
10-20 % methanol] and left overnight on 40v in 4℃.
After blocking the PVDF membrane in 1x Tris-buffered saline with 0.1% Tween (TBS-T)
and 5% skimmed milk for 1 hour on a rocker at room temperature it was followed with 2
hour anti-SYCP2 antibody incubation (1:1000 dilution in blocking buffer) on a rocker in
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4℃ (Millipore Anti-SYCP2 - Polyclonal Antibody. Cat. #ABE2622) And after that it was
washed 5x5 (5 times for 5 minutes) with TBS to prepare for horseradish peroxidase (HRP)
conjugated secondary antibody (Donkey Anti-rabbit Invitrogen Cat. #A16023 , 1:10,000 in
blocking buffer) in room temperature for 1 hour. And after that it was ready for protein
detection using Syngene G-Box fluorescence imager, and for that a HRP substrate luminol
is used (ECL) (Biorad #1705061)
2.4 Gene Cloning
2.4.1 Bacterial Culture +  DNA Purification
A glycerol stock of plasmid pCR-XL-TOPO (Figure 7) expressing full length SYCP2 was
purchased, (Cat. # ABIN3996587) Bacterial resistance: Kanamycin.
Aforementioned glycerol stock was grown on agar plate supplied with 50 ug/mL
Kanamycin antibiotic, using sterile techniques. And left to grow in 37℃ incubator
overnight. One colony was chosen and introduced in LB broth with 1:1000 dilution of
Kanamycin antibiotic, and left in shaking 37℃ incubator. Finally the liquid culture is
purified to isolate plasmids using Qiagen QIAprep spin Miniprep Kit (Cat. #27106).
Purified Plasmids were then quantified using Nanodrop and was a 145ng/uL.
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Figure 7 Genome map of TOPO plasmid expressing full length SYCP2
2.4.2 Designing Primers
Forward and Reverse primers were designed for subsequent gene cloning experiments.
(Table 2) Using Integrated DNA Technologies (IDT)
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Primer Tm Sequence Size in bp
Forward 5’ to 3’ 61.8℃
5’-GAT CGT CGA CCA AAA TGC CAA
TAA GAC CAG ATC-3’ 33
Reverse 5’ to 3’ 59.1℃
5’-GAT CGG ATC CAC ATT AGC ATT
TCT TTC ATG AG-3’
32
Table 2 Primer pair designed for PCR cloning
2.4.3 Polymerase Chain Reaction PCR
The PCR reaction were done using KAPA HiFi PCR kit and conducted per manufacturer’s
data sheet recommendation; cycle protocol is as follows (Table 3)
The reactions were done in triplicates and a water control, all on ice. Every reaction was
supplied with 0.3 μM of each forward and reverse primers, and 5uL of KAPA HiFi HotStart
ReadyMix.
The starting DNA sample was 10ng each. After the PCR round has finished to test whether
the protocol has worked 1 uL of each reaction was run on gel electrophoresis 1% Agarose
gel was chosen for better visualization of larger DNA [ 50 mL TAE + 0.5 g of Agarose +
2.5 uL Ethidium Bromide]. Samples were loaded with Invitrogen™ 1 Kb Plus DNA Ladder
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(Cat. # 10787018) run for 1 hour at 80 volts. The bands were cut off and purified using
New England BioLabs Monarch® DNA Gel Extraction Kit (Cat. #T1020)
Step Temperature Duration Cycles
Initial Denaturation 94℃ 3 minutes 1 cycle
Denaturation 98℃ 20 seconds 30 cycles
Annealing 60℃ 15 seconds 30 cycles
Extension 72℃ 3 minutes 30 cycles
Final Extension 72℃ 10 minutes 1 cycle
Table 3 Cycle parameters for KAPA HiFi HotStart
2.4.4 PCR Product Digestion + Ligation
Both the PCR product the full length SYCP2 gene and the target plasmid pEGFP-N1 was
digested with Promega BamHI (Cat. #R6021) + SalI (Cat. # R6051). Following
manufacturer’s suggested conditions. Digested Plasmid + Gene of interested were ligated in
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a 3:1 plasmid to gene of interest concentration using Invitrogen Anza™ T4 DNA Ligase
Master Mix (Cat. # IVGN2104).
2.4.5 Plasmid Construct and Bacterial Transformation
Successfully ligated product was transformed into in-house chemically treated (Calcium
Chloride) competent cells; 50 uL of thawed competent cells were mixed with 5uL of ligated
plasmids gently mixed by flicking tubes, incubated on ice for 30 minutes and then heat
shocked in 42℃ for 45 seconds and then added to prewarmed 37℃ SOC media left in
shaking incubator for 1 hour and after that plated on Kanamycin antibiotic supplied Agar
plates. Plasmids purified as steps shown in 3.3.1.
2.5 Immunohistochemistry (IHC)
Fixing of mouse testis tubules was done following (Namekawa and Lee, 2011) Mouse was
killed and testis placed in 1x PBS at room temperature, an incision made in testis, and the
tubules squeezed into the fixative without letting go of the tunica aluginea. Some tubules
(5-10) transferred to CSK buffer with Triton x100 and incubated for 6 mins at room
temperature. This step is important for removal of background. Tubules transferred into 4%
PFA and incubated for 10 mins and then transferred into fresh PBS and incubated for 5
mins. Tubules placed onto 20-30 uL of PBS on the back of a glass slide then tubules are
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teared between two watchmaker forceps for 10-20 secs until homogenised. The tubules are
transferred to a Eppendorf tube with 1.3 mL PBS.100 uL of suspension was loaded onto a
cytospin chamber and spun at 200 rpm for 10 mins at room temperature. After that slides
are washed with PBS for 5 min in a coplin jar and transferred and stored in 70% EtOH.
Immunostaining of mouse testis tubules was done following ( Xu H, Tong Z, Ye Q, et al.
2019)(Xu et al., 2019)
Slides washed in 1x PBS and then blocked with PBT [1% BSA + 0.1% Tween-20 in 50 mL
PBS] for 20 min at room temperature. Slides incubated in primary antibodies concentration
1:400 (Millipore Anti-SYCP2 - Polyclonal Antibody. Cat. #ABE2622) in PBT overnight at
4℃. Slides washed in 0.1% Tween-20 in PBS for 5 mins at room temperature followed by
incubation of secondary antibodies in PBT for 2 hr at room temperature. This was done in
the dark because secondary Antibodies were labelled with fluorophores. And Finally
mounted with DAPI and visualised in Fluorescent Microscope.
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3 Results
3.1 Bioinformatic Analysis
Normal expression of SYCP2 is almost completely restricted to testes. To assess the
expression profile of SYCP2 across normal tissues and cancer tissue, two different
bioinformatic analyses were performed. The first was using GTEx (Genotype Tissue
Expression) portal which is a public access database providing tissue specific gene
expression analysis. Using its visual interactive genomics tools we were able to obtain a
graph showing SYCP2 normal gene expression across different human tissues. (Figure 8)
The graph shows a comparison of expression throughout the different human tissues, we
can see there is a clear preference of expression to the testis.
The second bioinformatic analysis performed was using CBioPortal, (J et al., 2013) (E et
al., 2012) which is a public access interactive bioinformatic tool analysing transcriptional
cancer genomics data sets. There is an overwhelming amount of genomics data available
online and a tool like CBioPortal allows for easy access and interpretation of molecular
profiles of different cancer genomic data sets. The first graph (Figure 9) was done using
data from the global initiative; The Cancer Genome Atlas (TCGA) (Weinstein et al., 2013)
a large-scale collaboration that provides a comprehensive database of the most prevalent
cancers using tumour tissue samples from different cancer patients. The provided data by
this initiative allows for study comparisons and evaluation of different cancer types,
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exploring the genomic aberrations allows for a better understanding of cancer progression
and subsequently possible clinical implication.
All the Pan Cancer Atlas samples in TCGA were evaluated, 32 studies, 10967 samples. The
plot (Figure 9) shows the level of mRNA expression (vertical axis) and cancer type
(horizontal axis). The plot was sorted by median; we can observe that the highest
expression of SYCP2 is in cervical cancer followed by breast invasive carcinoma and so
on. But we can see there is not a significant difference in the level of expression between
the different cancer tissues.
These findings show that the gene is acting in a noncanonical manner leading to an
investigation to look into the mutations in the queried gene (Figure 10). As can be shown
the alteration in the gene is mostly an upregulation.
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Figure 8 SYCP2 expression across normal tissue.
Data is obtained using GTEx (GTEx Portal, no date) which is a public data resource set up by the NIH to study
gene expression. The graph shows the expression level of SYCP2 through different normal human tissue.
Although there is some level of expression in other tissues, the testes show the highest expression.
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Figure 9 CBioPortal(CBioPortal, 2013) plot showing SYCP2 expression across different cancers.]Data
obtained using CBioPortal which is a public access tool providing large scale cancer genomic data sets. This
graph shows the expression profile of SYCP2 across different cancers. Plot sorted by median; Showing the
highest expression level of SYCP2 is in cervical cancer. Comparing this graph to figure 8 there is a notable
significant upregulation of SYCP2 in cancer tissues when compared to their normal tissue. Although the plot
very clearly shows significant expression of SYCP2 there is not a --- pattern to their aberrant expression as
shown in the differently coloured circles, some are fusion mutations, some are deletions, some are
amplification etc.
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Figure 10 CBioPortal plot types of alterations of target gene SYCP2.
As shown previously, there are different types of mutations associated with SYCP2’s wrongful expression in
cancer tissues. This plot illustrates that gain of function and amplification mutations are the most found
aberrations in SYCP2 when it comes to its non-canonical expression in cancer tissue.
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3.2 Western Blots
3.2.1 Optimising Western blotting
Existing data shows SYCP2 being expressed on the mRNA, in order to investigate whether
the expression on the mRNA is followed by expression on the protein level; Western
blotting was performed. Testing both HPV-positive and HPV-negative cervical cancer cell
lines with mouse testis lysate as a positive control. The predicted size of the gene of interest
SYCP2 is ~200 kDa.
Figure 11 Western blot showing different protein lysates of HPV+ (SiHa) and HPV- (C33a) and mouse testis
lysate as a positive control. The predicted size of SYCP2 is ~200 kDa. SYCP2 Ab. Conc. 1:1000 overnight
incubation. Block 5% skimmed milk in TBST 0.1% Tween.
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The first blot performed was obtained using the BioRad Trans-Blot Turbo System as shown
in (Figure 11). The semi-dry transfer yielded faint uncharacterised bands. Across all
organisms the cell has a host of proteolytic enzymes which could interfere with the integrity
of proteins and cause degradation.(Farady and Craik, 2010) To address that and test
whether the bands witnessed are degradation products or in fact uncharacterised bands the
cells were treated with a proteosome inhibitor.
Figure 12 Western blot showing different protein lysates of HPV+ (SiHa) and HPV- (C33a) treated with MG132
in a time dependent manner [0hr, 30 min, 2hr, 3hr, 4hr] and mouse testis lysate as a positive control. The
predicted size of SYCP2 is ~200 kDa. SYCP2 Ab. Conc. 1:1000 overnight incubation. Block 5% skimmed milk
in TBST 0.1% Tween.
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The second blot shows the samples after treating with M132 the proteasome inhibitor
(Figure 12) but as can be seen, there are still uncharacterised bands. And so to optimise
transfer it has been shown in studies (Kong, Pu and Ma, 2008) that wet tank method of
transfer yields better results of larger molecular weight proteins and so a wet transfer was
attempted using Towbin buffer (Towbin, Staehelin and Gordon, 1979). As shown in (Figure
12) the transfer yielded clearer bands but still not at the predicted size. In further attempts
to optimise western blotting and eliminate uncharacterized bands (Figure 13) and (Figure
14) blots were incubated at 2 hours instead of overnight and washing steps extended. But as
is clearly visible one uncharacterised band remains in all blots at ~35 kDa.
Figure 13 Western blot showing different protein lysates of HPV+ (SiHa) and HPV- (C33a) treated with MG132
in a time dependent manner [0hr, 30 min, 2hr, 3hr, 4hr] and mouse testis lysate as a positive control. The
predicted size of SYCP2 is 200 kDa. SYCP2 Ab. Conc. 1:1000 2hr incubation. Block 5% skimmed milk in
TBST 0.1% Tween. Washing steps are also done in TBST 0.1% Tween. Exposure 49 seconds.
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Figure 14 Western blot showing different protein lysates of HPV+ (SiHa) and HPV- (C33a) treated with MG132
in a time dependent manner [0hr, 30 min, 2hr, 3hr, 4hr] and mouse testis lysate as a positive control. The
predicted size of SYCP2 is 200 kDa. (SYCP2 Ab. Conc. 1:1000)  2hr incubation. Block 5% skimmed milk in
TBST 0.025% triton. Washing steps done also in TBST 0.025% triton. Exposure 3 minutes.
Lysis buffers used in western blotting usually do a good job in extracting proteins
especially cytoplasmic or membrane bound however in this project case as the gene of
interest in nucleus based there is a chance that the protein is not being completely
solubilised extracted and being left in the pellet. To test that it is not a solubility issue and
the protein is not being lost during the protein extraction method and being left in the pellet
the insoluble have been tested using Western blotting (Figure 15) and as shown no clear
band is visible which eliminates that it is a solubility issue.
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Figure 15 Western blot showing the MPER-insoluble pellets of HPV+ (SiHa) and HPV- (C33a) treated with
MG132 in a time dependent manner [0hr, 30 min, 2hr, 3hr, 4hr] and mouse testis lysate as a positive control.
The predicted size of SYCP2 is 200 kDa. Antibody concentration was SYCP2 1:1000 and overnight incubation.
The blot shows uncharacterised bands and none of the predicted molecular weight, confirming that the protein
is not left behind with insoluble pellets during protein extraction.
60
Aroub Yousef I Almubarak
3.3 Immunofluorescence Microscopy
To visualise the localised expression of SYCP2 in normal tissue (tissue used here is mouse
testis) the same antibody (Millipore Anti-SYCP2 - Polyclonal Antibody. Cat. #ABE2622)
The western blotting results observed had some uncharacterised bands, although there were
bands in the predicted molecular weight the presence of other bands led to a question of
whether or not the purchased antibody is recognising the correct epitope of the gene of
interest, because that would hinder the validity of the result. This experiment (figure 16)
was conducted to assess if the antibody is recognizing the correct epitope and it confirmed
that indeed it is recognising the correct epitope.
Figure 16 Mouse testis microtubules with anti-SYCP2 antibody. Left: Positive control SYCP2 concentration of
1:400. Right: Negative control with only secondary antibody. This experiment was conducted to confirm that
the purchased antibody was recognising the correct epitope of the gene of interest. To confirm the western blot
results observed in (figure14) and (figure15), and eliminate the possibility that the bands observed might be
uncharacterised bands.
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3.4 Cloning Gene of interest into Plasmid Construct
To validate the western blot results this experiment was performed as the first step to
validate protein expression of SYCP2 through assessing a transiently expressed form of the
protein from extrachromosomal construct (pEGFP-N1). Visualising the transiently
expressed SYCP2 protein on western blot would validate the primary results and would
eliminate any questions of solubility, considering that SYCP2 is localised in the nucleus
there is still a possibility that it is not being solubilised properly and what was observed is
uncharacterised bands. Assessing it using western blotting from extrachromosomal
expressed protein would eliminate that possibility.
To express the gene of interest transiently; SYCP2 was amplified from purchased TOPO
plasmid expressing the full length gene using HiFi PCR ( Figure 17). Afterwards, the PCR
product was digested with BamHI + SalI along with the plasmid construct pEGFP-N1
(Figure18). And ligated using Invitrogen Anza™ T4 DNA Ligase Master Mix. (Figure 19)
shows the successfully transformed and isolated construct allowing expression of SYCP2
as a C-terminal GFP-fusion protein.
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Figure 17 KAPA HIFI PCR product. Starting product was 10ng of TOPO plasmid
Figure 18 pEGFP-N1 (third and fourth wells) after restriction digestion with Promega; BamHI and SalI and
SYCP2 PCR product (last and second last wells) after restriction digestion with Promega; BamHI and SalI.
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Figure 19 pEGFP-N1 plasmid expressing full length SYCP2
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4 Discussion:
As it has been established in previous studies, SYCP2 is found wrongfully overexpressed in
HPV+ cancer cell lines, SYCP2 being part of the synaptonemal complex and the role it has
in meiotic recombination if it is expressed outside the controlled environment of
meiotically dividing cells, could lead to an environment of genetic instability. Studies
conducted showed expression on the mRNA level, to investigate any clinical potential with
this finding further experimentation needs to be conducted. Which is what this project set
out to investigate; if the expression on the mRNA level is followed by expression on the
protein level. Experiments were conducted to assess the aberrant expression of SYCP2 on
the protein level in cervical cancer cell lines both HPV+ and HPV-.
There is still very little known in the literature about the aberrant expression of this gene;
when normally expressed it aids with the conserved well known process of homologous
recombination that happens in meiosis. And it has been explored that not only does it offer
a structural role it also plays a role in the choice of recombination pathway in order to
accomplish the genetic diversity of progeny which is where DNA amplification differs in
meiosis from mitosis in the resulting daughter cells. And by the use of bioinformatic tools
we were able to visually compare the difference of expression in normal tissue against the
wrongful expression in cancer tumour tissue (Figure 8) (Figure 9). And as can be seen
when expressed normally it is almost completely restricted to testes but when expressed
aberrantly it can be seen in an array of cancers.
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4.1 Assessment of SYCP2 Protein Expression
Western blotting was attempted and although it was optimised and better transfer was
achieved and more defined bands were observed, there were still uncharacterised bands of
an unexpected molecular weight. This could be due to a few reasons; it could be that the
protein observed is a degradation product, that was addressed by treating the cells with
proteasome inhibitor MG132; which yielded clearer bands but still not at the expected
level. Moreover, it has been observed in adenoviruses that while the virus hijacks the host
cell machinery, translation of host mRNA is shut down to facilitate the translation of viral
proteins. (Schreiner, Wimmer and Dobner, 2012) To address this possibility a transient
infection of the cancer cell lines were attempted by purchasing full length SYCP2 gene and
successfully inserted into GFP tagged plasmid (Figure 19) to follow that with performing
western blotting to assess if the bands observed were due to a molecular event or a defect in
the antibody. This was limited due to COVID19 pandemic and subsequent lockdowns. The
GFP tagged plasmid would have been first digested with BamHI and SalI to confirm the
plasmid is with the correct gene insert and then followed with transient transfection. And
the process of western blotting would be achieved subsequent to that.
Because of the localization of the protein in the nucleus it could be that the lysis buffer
cannot completely solubilise the proteins and the protein of interest is left behind in the
pellet. Although this has been addressed by performing western blotting on the insoluble
(pellets) and yielded no bands in the expected molecular weight, it still cannot be
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completely excluded as the pellet is a mixture of cellular debris and could agglutinate to
form complex structure post lysis not allowing for proper separation and thus proper
recognition of the antibody. This could be addressed in future work by using nuclear
protein extraction which digests cytosolic proteins following with hypotonic buffer
allowing the nucleus to swell and homogenised to allow nuclear proteins to be extracted.
The antibody used in the experiments is a polyclonal antibody, the uncharacterised bands
observed could be due to the fact that a polyclonal antibody although would bind to the
correct epitope of the antigen of gene of interest but could also recognise and bind to other
epitopes (Lipman et al., 2005) as opposed to monoclonal antibodies famously discovered
and awarded Nobel prize Köhler and Milstein 1975 (Köhler and Milstein, 1975) where
splenic B cells and myeloma cells are fused producing hybridomas producing unique
specific monoclonal antibodies with higher affinity would specifically bind to the gene of
interest. In an attempt to address that; Immunofluorescence microscopy was conducted with
the same antibody to explore whether or not it is in fact attaching to the right epitope. And
indeed, the results showed that it is picking up the SYCP2 signal but there is a significant
amount of background and especially with the acrosome (Figure 20) that it is clearly
picking up a signal for.
More interestingly, demonstrated in (Ahmad et al., 2005) witnessing a difference in
observed molecular weight to the predicted molecular weight could mean a post
translational modification event is occurring such as alternative splicing.
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4.1.1 Human papillomavirus regulation of gene expression effect on host cell genes.
HPV depends extensively on the process of alternative splicing (Johansson and Schwartz,
2013) (Graham and Faizo, 2017) given its small genome to produce its repertoire of viral
proteins. Recent advances in RNA sequencing allowed research to be conducted to look
into what viral infection effect can have on host splicing (Ashraf et al., 2019) in the study
there is a significant amount of host genes showing altered mRNA splicing post viral
infection. This molecular event can be due to the virus altering the host splicing machinery
as described in 4.1 or a host immune response to the infection (Chang and Zhang, 2017).
68
Aroub Yousef I Almubarak
4.2 SYCP2 possible role oncogenic molecular events
It is unknown why SYCP2 is switched on in HPV cancers. It has been described that HPV
favours one DNA repair pathway to another, and as the SC works the same way for meiosis
it could be that it is switched on to help the viral infection and production of its progeny. In
line with what was found in western blot results, if indeed the SYCP2 protein is
alternatively spliced then it could have a completely different function and effect in either
viral infection or oncogenesis.
4.2.1 Alternative Lengthening of Telomeres
Telomeres are stretches of DNA repetitive (TTAGGG) that cap and protect the
chromosomes during replication and maintain genomic integrity such as preventing them
from fusing with other chromosomes. With every cell cycle the telomeres shorten, and
eventually trigger cellular senescence. This is to maintain the number of cell divisions a cell
can undergo. One way for a cell to become a cancer cell is undergoing genetic
modifications and entering what is called a “crisis” state having escaped cellular
senescence. One mutation is upregulation in the human TERT gene (hTERT) which
expresses the enzyme telomerase and initiates uncontrolled proliferation of telomeric DNA
which is a known hallmark of cancer. However with some tumours cells finds a way to
maintain telomeric DNA, independent of telomerase an alternative pathway called;
Alternative Lengthening of Telomeres (ALT) the pattern of the telomeric DNA suggests the
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ALT cells using the HR pathway using a DNA template activating homologous
recombination pathway for DNA repair activated by RAD51 for maintaining the
telomeres. The cells are heterogeneous and there are fluctuations in the length of the
telomere in each cell and chromosome fusion in some. If SYCP2 is creating neoplastic
conditions; considering the role the SC has in meiotic recombination, this molecular
process could be how SYCP2 is aiding oncogenesis.
4.2.2  What wrongful expression of SYCP2 means to oncogenic progression
As previously discussed in 1.2.1 the activation of meiotic genes in somatic cells are factors
leading to progression of cancer. This is due to the unique characteristics meiosis specific
genes have that when wrongfully expressed function as oncogenic drivers, such as
favouring interhomolog repair which leads to loss of heterozygosity, the genesis of DSB,
and alterations of the transcriptional landscape and epigenetic modification (Feichtinger
and McFarlane, 2019). This study aimed to assess whether the expression of SYCP2 on the
mRNA level is followed by expression on the protein level, when explored via
bioinformatic tools we can clearly see the difference in expression when comparing the
mRNA expression levels of SYCP2 in normal tissue against tumour tissue as observed in
(Figure 8), (Figure 9). Furthermore, barring some difficulties faced with wet lab approach
we can confidently attest there is expression being picked up by antibodies against the
SYCP2 protein. This proposes an epigenetic alteration module of SYCP2 overexpression in
HPV+ cancers.
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4.3 Conclusions and Future Prospects
HPV makes a unique model because we can readily examine the changes on the molecular
level in what it could mean to oncogenesis. It has been shown that SYCP2 is overexpressed
and whilst difficulties were faced in the assessment of protein expression, further
experimentations can investigate the possibility of alternative splice events using
combination of western blotting and transcript identification by rapid amplification of
cDNA ends (RACE) to assess which splice forms of SYCP2 are expressed in a panel of
HPV16+ cancer cell lines. And to investigate if SYCP2 is partaking a role in HPV
infection, using CRISPR-Cas9 to delete SYCP2 in normal keratinocytes (NIKS) will allow
investigating if HPV16 is able to complete genome replication and amplification in
organotypic epithelia generated from SYCP2-KO cells. A question remains if the results
found are experimental shortcoming or a finding that there is a splicing event, although this
finding does not demonstrate an active role of this gene in cancer progression the data
warrants future investigations.
Further research needs to be conducted to investigate the role SYCP2 could have, if it is
switched on after the aborted cycle of HPV and lead to oncogenesis or if it is switched on
early on to aid HPV in its viral replication. Or if that it is simply a by-product of the various
molecular changes HPV cancers present that have no substantial role in viral infection or
oncogenesis.
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